Quantification of drugs of abuse in human blood by TurboFlow chromatography coupled to tandem mass spectrometry for use in clinical research

Significance of the Topic

Quantitative analysis of drugs of abuse in human blood is fundamental for clinical research applications including therapeutic monitoring and toxicology studies. Rapid and sensitive detection is crucial for accurate assessment of patient compliance overdose cases and pharmacokinetic investigations.

Objectives and Study Overview

The study aimed to develop and validate an analytical workflow for quantifying fourteen commonly abused substances in human blood samples. This method was designed to deliver high throughput minimal sample handling and robust performance suitable for clinical research settings.

Methodology and Instrumentation

Sample Preparation

• Blood samples underwent protein precipitation after addition of zinc sulfate solution and deuterated internal standards
• Supernatants were obtained by centrifugation and directly transferred for analysis

Online Sample Cleanup and Chromatography

• TurboFlow online extraction facilitated direct loading of the supernatant onto a trap column for rapid cleanup
• Analytes were separated on a biphenyl analytical column with gradient elution in under five minutes

Mass Spectrometry Detection

• Detection was performed in positive electrospray ionization mode using selected reaction monitoring
• Two mass transitions per analyte allowed quantification and confirmation

Used Instrumentation

• Transcend TLX system with TurboFlow online extraction technology
• TurboFlow Cyclone trap column and Accucore biphenyl analytical column maintained at 30°C
• TSQ Quantis triple stage quadrupole mass spectrometer with heated electrospray ionization

Main Results and Discussion

Linearity and Sensitivity

• Calibration curves showed linear response over 2.5 to 100 ng/mL with correlation coefficients above 0.99
• Limits of quantification ranged from 0.01 to 0.5 ng/mL using TurboFlow, representing up to fivefold sensitivity gain over conventional LC approaches

Accuracy and Precision

• Analytical bias remained within ±7 % for control samples at low and high levels
• Intra-assay precision was below 7.3 % and inter-assay precision below 7.8 % across all analytes

Carryover was negligible, demonstrating suitability for high throughput operation.

Benefits and Practical Applications

• Automated online cleanup minimizes manual handling and reduces sample preparation time
• Rapid chromatographic runtime supports large sample cohorts
• Enhanced sensitivity and robustness meet stringent clinical research quality requirements

Future Trends and Potential Applications

Potential developments include expansion to additional drug panels, incorporation of high resolution mass spectrometry for non-targeted screening, and integration with automated sample management platforms. Adaptation to portable devices and lab-on-a-chip formats may extend its use to point-of-care testing and on-site forensic investigations.

Conclusion

The presented TurboFlow-enabled LC-MS/MS workflow offers a rapid, sensitive, and reproducible solution for quantifying a broad range of drugs of abuse in human blood. Its performance characteristics align with the demands of clinical research laboratories, facilitating reliable data generation with minimal sample preparation.